Pfizer Inc. (PFE – Analyst Report) posted fourth quarter 2015 earnings of 53 cents per share, a penny above the Zacks Consensus Estimate but down 2% from the year-ago period.

Revenues, which grew 7% to $14.047 billion, were well above the Zacks Consensus Estimate of $13.605 billion.

Full year earnings came in at $2.20 per share, down 3%, while revenues declined 2% to $48.851 billion.

Prevnar, Ibrance Perform Well

While currency movement cut Pfizer’s fourth quarter revenues by 7% ($934 million), operational growth was 14% ($1.9 billion). International revenues declined 9% to $7.3 billion. Meanwhile, U.S. revenues grew 33% to $6.7 billion.

Although the standalone Global Established Pharmaceutical (GEP) and Consumer Healthcare segments recorded a decline in revenues, the Global Innovative Pharmaceutical (GIP), Global Oncology and Global Vaccines segments recorded growth.

The standalone GEP segment recorded a 21% decline in revenues, which came in at $5.1 billion. Factors like the presence of generic competition for Celebrex, the Jan 2015 entry of generic competition for Zyvox IV and Lyrica in certain developed EU markets affected revenues.

GIP segment revenues grew 3% to $3.9 billion reflecting the strong performance of Lyrica in the U.S. and Japan, Xeljanz in the U.S. and Eliquis across the world.

Consumer Healthcare revenues declined 2% to $930 million. Nexium 24HR demand in the U.S. remained strong.

Global Oncology revenues increased 52% to $928 million with performance being driven by Xalkori, Sutent and recently launched Ibrance which contributed $315 million to sales, significantly above third quarter 2015 sales of $230 million.

Global Vaccine revenues grew 45% to $1.9 billion. Prevnar 13 was positively impacted by continued strong uptake among adults reflecting the success of commercial programs, increased demand in the flu season as well as the timing of government purchases for the pediatric indication.